drug · antibody drug conjugate
raludotatug deruxtecan
Phase 3updated 3mo agoby Daiichi Sankyo Co Ltd🔗 ChEMBL
Phase 3community read0 votes
🐶 often sniffed alongside
top 3Antibody drug conjugate drug with a maximum clinical stage of Phase 2, with 1 investigational indication.
indications
indications
NSCLC
all catalysts(1)
Trials studying raludotatug deruxtecan
- phase2A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
- phase2A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
- phase2A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
- phase2A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 25m ago
Found something off?
comments(0)
5-min edit window · permanent after that